Next Article in Journal
36th Annual CAPO Conference: Advocating for All: Psychosocial Oncology at the Intersections of Equity, Diversity, and Inclusion, 8–10 June 2021
Previous Article in Journal
The Usefulness of Spectral Mammography in Surgical Planning of Breast Cancer Treatment—Analysis of 999 Patients with Primary Operable Breast Cancer
Review

Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases

1
Princess Margaret Cancer Centre, Radiation Medicine Program, University Health Network, Toronto, ON M5G2M9, Canada
2
Department of Radiation Oncology, University of Toronto, Toronto, ON M5G2M9, Canada
3
Western National Medical Center, Department of Radiation Oncology, Mexican Institute of Social Security (IMSS), Belisario Domínguez 1000, Guadalajara 44340, Jalisco, Mexico
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(4), 2560-2578; https://doi.org/10.3390/curroncol28040233
Received: 5 May 2021 / Revised: 5 July 2021 / Accepted: 6 July 2021 / Published: 15 July 2021
(This article belongs to the Section Thoracic Oncology)
Lung metastases are the second most common malignant neoplasms of the lung. It is estimated that 20–54% of cancer patients have lung metastases at some point during their disease course, and at least 50% of cancer-related deaths occur at this stage. Lung metastases are widely accepted to be oligometastatic when five lesions or less occur separately in up to three organs. Stereotactic body radiation therapy (SBRT) is a noninvasive, safe, and effective treatment for metastatic lung disease in carefully selected patients. There is no current consensus on the ideal dose and fractionation for SBRT in lung metastases, and it is the subject of study in ongoing clinical trials, which examines different locations in the lung (central and peripheral). This review discusses current indications, fractionations, challenges, and technical requirements for lung SBRT. View Full-Text
Keywords: lung SBRT; oligometastatic disease; lung cancer; lung metastases lung SBRT; oligometastatic disease; lung cancer; lung metastases
Show Figures

Figure 1

MDPI and ACS Style

Gutiérrez, E.; Sánchez, I.; Díaz, O.; Valles, A.; Balderrama, R.; Fuentes, J.; Lara, B.; Olimón, C.; Ruiz, V.; Rodríguez, J.; Bayardo, L.H.; Chan, M.; Villafuerte, C.J.; Padayachee, J.; Sun, A. Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases. Curr. Oncol. 2021, 28, 2560-2578. https://doi.org/10.3390/curroncol28040233

AMA Style

Gutiérrez E, Sánchez I, Díaz O, Valles A, Balderrama R, Fuentes J, Lara B, Olimón C, Ruiz V, Rodríguez J, Bayardo LH, Chan M, Villafuerte CJ, Padayachee J, Sun A. Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases. Current Oncology. 2021; 28(4):2560-2578. https://doi.org/10.3390/curroncol28040233

Chicago/Turabian Style

Gutiérrez, Enrique, Irving Sánchez, Omar Díaz, Adrián Valles, Ricardo Balderrama, Jesús Fuentes, Brenda Lara, Cipatli Olimón, Víctor Ruiz, José Rodríguez, Luis H. Bayardo, Matthew Chan, Conrad J. Villafuerte, Jerusha Padayachee, and Alexander Sun. 2021. "Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases" Current Oncology 28, no. 4: 2560-2578. https://doi.org/10.3390/curroncol28040233

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop